READING, England--(EON: Enhanced Online News)--LGC, an international leader in the laboratory services, measurement standards, reference materials, genomics and proficiency testing marketplaces, and TranScrip Partners, a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management, have today announced a strategic alliance which will allow both parties to combine and enhance their offerings to clients, particularly in the areas of anti-infectives and respiratory disease.
“TranScrip have an enviable reputation for drug development, registration and post licensing support in anti-infectives, particularly antibiotics, and our alliance with LGC will allow us to extend this capability into vital laboratory support for these programmes. We are therefore delighted about the two companies coming together.”
TranScrip Partners supply a wide range of services including drug development and operations, regulatory affairs, microbiology, medical writing, translational medicine, drug safety and pharmacovigilance. LGC is a provider of high-integrity analytical laboratory services to support drug discovery, development and manufacture. With last year’s acquisition of Quotient Bio Analytical Sciences, LGC also has a leading bioanalytical facility with expertise spanning small molecules, biopharmaceuticals, biomarkers, microbiology and molecular services.
Dr David Griffiths, Director, Pharmaceutical Services at LGC, said, “We’re really excited by this development. LGC’s high quality laboratory services and TranScrip’s expertise in drug development strategy, medical writing and regulatory affairs complement each other beautifully. Whilst both companies support all therapeutic areas, we have a combined strength in anti-infectives and we are looking forward to discussing this alliance with our clients at the forthcoming ICAAC conference.”
Felicity Gabbay, Managing Partner at TranScrip Partners, added, “TranScrip have an enviable reputation for drug development, registration and post licensing support in anti-infectives, particularly antibiotics, and our alliance with LGC will allow us to extend this capability into vital laboratory support for these programmes. We are therefore delighted about the two companies coming together.”
On 3 October LGC is hosting an Autumn Seminar on Respiratory Product Development at their site in Fordham, Cambridgeshire, UK. Among the speakers will be TranScrip Partners’ Professor Tim Higenbottam, presenting on ‘Regulatory strategies for respiratory product development: opportunities and pitfalls’. To see the full programme and to register, please click here.
LGC is exhibiting at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) from 10-13 September in Denver, CO, USA. To find out more about this exciting new development between LGC and TranScrip please visit booth #419.
Notes to editors:
LGC is an international science-based company and market leader in the laboratory services, measurement standards, genomics, reference materials and proficiency testing marketplaces. LGC operates in a variety of markets – including, but not confined to, Food & Agriculture, Government, Pharmaceuticals and Biopharmaceuticals and Sports – which underpin the safety, health and security of the public and the regulation of industry, for both private and public sector clients.
With headquarters in Teddington, South West London, LGC employs over 2,000 staff, operating out of 22 countries worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025.
Set up in 1842 as the Laboratory of the Government Chemist, for more than 100 years LGC has held the unique function of the Government Chemist in the UK. LGC was privatised in 1996 and is now majority-owned by funds managed by Bridgepoint.
About TranScrip Partners
TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management.
TranScrip Partners are strategic thinkers who do, and doers who think strategically.
Working for more than 80 companies across 4 continents, we challenge the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.